Shuttle Pharmaceuticals Holdings Inc
For the period ended Dec 31, 2024. Filed Feb 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 26, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 14. Principal Accountant Fees and Services
The following table represents fees for professional audit services for the audit of the Company’s annual financial statements for the fiscal years ended December 31, 2024 and December 31, 2024 rendered by Forvis Mazars, LLP.
| Fiscal year ended December 31, | ||||
|---|---|---|---|---|
| 2024 · 2023 | ||||
| Audit Fees 1 | $524,303 | $429,555 | ||
| Other Audit Fees | $ | - | $ | - |
| Tax Fees 2 | $ | - | $ | - |
| Total fees | $524,303 | $429,555 | ||
| 1. | Audit fees consist of fees for professional services rendered by the principal accountant for the audit of the Company’s annual financial statements and review of the financial statements included in the Company’s Form 10-K and Form 10-Q and for services that are normally provided by the accountant in connection with statutory and regulatory filings or engagements. Fees include out of scope costs related to convertible notes and warrants. |
| 2. | Tax fees consist of professional services rendered by our principal accountant for tax compliance, tax advice and tax planning. |
Audit Committee Pre-Approval Policies
The Audit Committee is tasked with pre-approving any non-audit services proposed to be provided to the Company by the independent auditors.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.